Living on the Spectrum — Show Notes

Overview: This episode reviews a major private investment in autism research, new genetics findings and their limits, an expression of concern on a highly cited mouse study, a research-roundup item on acetaminophen and brain organoids, and three ADDitude advice pieces on social slip-ups, conversations, and oversharing. The discussion distinguishes announced or planned research from results, group-level genetic findings from individual prediction, and optional social strategies from requirements.

Private initiative makes ‘historic’ investment in autism research

The Transmitter reported on 13 October 2026, in a piece by Madeline Shaw, that ARIA—Aligning Research to Impact Autism—has publicly committed more than $450 million to autism research, with about $300 million announced since June. ARIA was launched by the Sergey Brin Family Foundation in 2024. The article says the amount rivals the U.S. National Institutes of Health’s annual autism research budget. ARIA focuses on profound autism and potential autism therapies.

The structure is six hubs: five research hubs and an IMPACT Network of 20 hospitals and universities intended to run clinical trials arising from the other hubs’ work. There is also a centralized biobank and data-sharing. One large grant is $46 million to UCSF’s Quantitative Biosciences Institute for protein-protein interaction work. Another $46 million goes to Harvard and Yale for four projects in human developmental neurobiology. At Harvard, that includes growing hundreds of brain organoids from blood samples to model brain development beginning in gestation. At Yale, researchers plan a connectome mapping the developing brain using human and primate tissue, plus single-cell genomic analyses. A Harvard-based AI effort aims to build virtual cell models of the developing brain.

Ekemini Riley, ARIA’s managing director, is quoted saying the goal is to get at the why and the how so they can develop rational treatments, and that this is just the beginning. Thomas Insel, former director of the National Institute of Mental Health, calls the investment historic and says, “We have something to chase now,” pointing to more than 200 genes associated with autism. Helen Tager-Flusberg is quoted saying the scope, integration, and size are different from anything NIH has or could mount, and predicts ARIA is likely to transform the autism research landscape. The episode notes that this is an attributed prediction, not a measured outcome.

The article also describes federal funding uncertainty for agencies like NIH under the Trump administration, and mentions that last month the Department of Health and Human Services announced a new autism research program called SPECTRA. It points to a broader trend of private foundation funding: SFARI has an annual budget of about $100 million and has contributed around $750 to $760 million since 2006.

The discussion stresses that the article describes announced investments and planned work, not study results. It does not report outcomes. A large investment can be important while still taking years to produce clinically useful answers, and the episode acknowledges concerns about overselling to families.

Quote: Mark Daly on genetic results and patient trajectories

Holly Barker wrote about three preprints in The Transmitter on 8 October 2026. The headline number is 253 high-confidence autism-linked genes, up from 72 in the same team’s 2022 study. The gene-list analysis looked at exome sequences from 62,429 autistic people in the Autism Sequencing Consortium and three other major cohorts. Two of those cohorts, the Simons Simplex Collection and SPARK, are funded by the Simons Foundation, which also supports The Transmitter.

The work grouped the 253 genes into six clusters based on overlap with schizophrenia, bipolar disorder, epilepsy, and other neurodevelopmental conditions. Genes associated with autism alone, or autism and schizophrenia, were less likely to harbor de novo variants than genes also implicated in neurodevelopmental conditions more generally. When the researchers grouped the six clusters into two broader categories, synapse assembly was more common among autism-specific genes, while transcriptional regulation was enriched among genes linked to a wider range of conditions.

Children carrying a rare variant in a gene connected to many conditions were more likely to show developmental delays and less likely to reach developmental milestones than children carrying a variant in an autism-specific gene. The episode notes this is a group-level finding and does not tell you what will happen to one child. Mark Daly, one of the investigators, is quoted saying, “We are not yet at a point where individual genetic results can accurately predict patient trajectories.” He also cautions that the six clusters are probabilistic but not predictive.

In the third preprint, de novo variants accounted for 3.4 percent of the variation in people’s genetic susceptibility to autism. Among people carrying spontaneous variants, half of that variance—about 1.7 percent—could be explained by just 15 genes, most associated with severe neurodevelopmental conditions. About 7 percent of autistic people carry a spontaneous variant predicted to increase the likelihood of having the condition. The 20 percent most constrained genes accounted for about 90 percent of the variation in genetic likelihood attributable to de novo variants.

The forecasting analysis also predicted that many autism-linked genes remain undiscovered, including roughly 25 percent of genes strongly linked to the condition. Maria Chahrour, who was not involved, notes that most autistic people still lack a rare-variant explanation and that cohorts need more ancestral diversity. The episode describes the science as real but incomplete.

Highly cited autism paper earns expression of concern over data duplications

A highly cited 2017 Nature paper linking maternal gut bacteria to autism-like traits in mice received an expression of concern, not a retraction. The Transmitter reported on 16 October 2026 that Nature issued the notice because of apparent data duplications. The paper has been cited more than 680 times. The notice cites recurring identical values for two sociability measures across multiple datasets in 10 different figures. The authors could not locate all the original raw data files after lab relocations.

The expression of concern notes a correction for a duplicated image that Sholto David flagged on PubPeer in September 2025. While reviewing that image issue, investigator Jun Huh went through the data and found what Dan Littman describes as a whole bunch of duplicate numbers. Huh could not verify the source and notified Nature. Nature’s editor, Francesca Cesari, said the journal investigated carefully and, because the authors could not locate all the original raw data files, determined an expression of concern was the most appropriate course. All authors agreed except first author Sangdoo Kim and Soyoung Ha, who did not respond to Nature’s communications or could not be reached.

Some authors say the conclusions still hold. Huh says the study’s conclusions remain unchanged and have since been corroborated by subsequent studies. John Lukens says the core concepts have been reproduced and the data duplications should not take away from what was reported. Critics are less sanguine. Mu Yang says the duplicated data are critical for the conclusions, and that the extent to which the duplications change the findings can only be evaluated by comparing incorrect data with correct raw data. Kevin Mitchell says research linking the gut microbiome to autism is plagued by conceptual and methodological flaws, and that the literature is all over the place.

The episode advises listeners not to treat one mouse study as a settled explanation for autism, and not to treat an expression of concern as proof that every related finding is wrong. It is a signal about data integrity and uncertainty, and it shows why replication and raw-data access matter.

Research roundup

The roundup by Jill Adams, published 13 October 2026, summarizes a study exposing lab-grown brain tissue to acetaminophen at a stage modeling late first-trimester development. The tissue showed no changes in size, structure, cell survival, the connections between neurons, or the mix of developing brain cells. Some changes in gene activity appeared at the highest dose, but gene activity looked normal later.

The roundup says the findings are consistent with large-scale studies showing that acetaminophen use during pregnancy does not increase the likelihood of having a child with autism. The episode notes that the conclusion about likelihood comes from the large-scale studies cited as consistent with the organoid findings, not from the organoid experiment itself. The organoid work explores possible direct biological mechanisms and does not report clinical outcomes. The roundup does not give sample sizes, doses, effect estimates, or methods, so it is a brief summary rather than something to base personal medical decisions on. Anyone with questions about medication during pregnancy should talk with their clinician.

Is Your ADHD Causing Social Slip-Ups?

Ari Tuckman’s ADDitude advice piece is practical guidance, not a research study; the episode notes there are no sample sizes or outcome data. It uses three adults: Steph, who interrupts when she is excited or nervous; Roberto, who was told he looked lost in thought and bored; and James, who overcommitted and canceled plans at the last minute.

The advice includes identifying two or three recurring patterns, using a discreet partner signal, repairing a misstep with a sincere explanation, making eye contact when you catch yourself drifting, asking for repetition, and checking your calendar before agreeing to something new. Steph meets her boyfriend’s parents, cuts them off to make her own points, and later sends a thank-you card explaining that her excitement got the best of her. The episode describes that as repair, not a cure for interrupting.

The article says people with ADHD often know what they should do but have trouble doing it in the moment. The discussion frames that as a practical distinction, not a moral failing.

The ADHD Guide to Naturally Flowing, 'Normal' Conversations

Sharon Saline’s ADDitude piece addresses unspoken social rules. It says assumptions that everyone knows these rules do not account for neurodiversity—some people with ADHD, learning differences, and autistic people may not understand them or may never have learned them, and anxiety can affect social skills too.

The APPLE mnemonic is: Ask to join a conversation and assess what is happening before jumping in. Pay attention to physical proximity and volume—where you are standing, how loud you are, whether you are matching the room. Participate with reflective statements like “So what you’re saying is...” or “Oh, wow, you just got that new job. Fantastic.” Lay off self-criticism and do not let the internal negative voice run the show. Enjoy connecting—share what is interesting about you and learn what is interesting about others. The article also suggests a buddy signal for volume or overenthusiasm, and if you have spaced out, discreetly asking a nearby friend what is being discussed.

The episode notes this is an advice piece without sample sizes or outcome data. It also notes that some body-language advice relies on general social norms and does not account for cultural or individual variation.

How to Break Your Habit of Oversharing

Caroline Maguire’s ADDitude piece discusses impulsivity, wanting to connect, and the feeling of clicking with someone after five minutes. The advice is to notice triggers, do some “social spying” to see what others share, gamify asking questions before talking about yourself, check trust and familiarity, assess your emotional state, and practice tighter stories. It also says practice, not perfection.

The article frames oversharing as driven by impulsivity, a desire for connection, and social-skills challenges. It does not give prevalence estimates, and it makes some broad claims about neurodivergent minds that are not backed by cited research in the piece. The episode suggests treating the strategies as optional tools, not a diagnosis or a rulebook. The article itself says it is not all or nothing—if a detail is edging into oversharing territory, you can steer toward a more neutral talking point instead of discarding it completely.

The discussion also addresses concerns that these tips can become “act normal” homework, especially for kids already told their natural way of communicating is wrong. It frames the strategies as optional choices a person can make if they want a particular social outcome, not requirements for being acceptable. It distinguishes choosing to use a buddy signal because it helps in a meeting from being told you must suppress who you are, and suggests taking what helps, leaving the rest, and respecting boundaries.

Podcast Transcript

Aaron: Welcome to Living on the Spectrum. I'm Aaron, and with me is Jamie. Today we're starting with a big funding story, then moving through some new genetics, a research-integrity notice that matters, a quick check on acetaminophen, and finally some very practical questions about social slip-ups, conversations, and oversharing. Jamie, the funding headline: ARIA, launched by the Sergey Brin Family Foundation in 2024, has publicly committed more than $450 million to autism research, with about $300 million announced since June.

Jamie: That's right. The Transmitter reported this on 13 October 2026, in a news piece by Madeline Shaw. The article says that amount rivals the U.S. National Institutes of Health's annual autism research budget. ARIA stands for Aligning Research to Impact Autism, and it's focused on profound autism and potential autism therapies. The structure is six hubs—five research hubs and an IMPACT Network of 20 hospitals and universities that's meant to run clinical trials coming out of the other hubs' work.

Aaron: So this isn't a single study. It's an infrastructure investment.

Jamie: Exactly. The article describes announced investments and planned work, not study results. There's a centralized biobank and data-sharing. One large grant is $46 million to UCSF's Quantitative Biosciences Institute for protein-protein interaction work. Another $46 million goes to Harvard and Yale for four projects in human developmental neurobiology. At Harvard, that includes growing hundreds of brain organoids from blood samples to model brain development beginning in gestation. At Yale, researchers plan a connectome mapping the developing brain using human and primate tissue, plus single-cell genomic analyses. And there's a Harvard-based AI effort to build virtual cell models of the developing brain.

Aaron: When I hear "profound autism" and "therapies," I think about families who are desperate for something that helps. But also—this can sound like a cure is around the corner. Is that what the article says?

Jamie: Not quite. The article quotes Ekemini Riley, ARIA's managing director, saying the goal is to get at the why and the how so they can develop rational treatments, and that this is just the beginning. It's future-oriented. Thomas Insel, former director of the National Institute of Mental Health, calls the investment historic and says, "We have something to chase now," pointing to more than 200 genes associated with autism. Helen Tager-Flusberg is quoted saying the scope, integration, and size are different from anything NIH has or could mount, and she predicts ARIA is likely to transform the autism research landscape. But that's an attributed prediction, not a measured outcome.

Aaron: And there's the federal funding uncertainty piece.

Jamie: Yes. The article says Tager-Flusberg describes the future of federal funding for agencies like NIH under the Trump administration as increasingly uncertain. It also mentions that last month the Department of Health and Human Services announced a new autism research program called SPECTRA. And it points to a broader trend of private foundation funding—SFARI has an annual budget of about $100 million and has contributed around $750 to $760 million since 2006. So this is a major shift in who's paying for what. That doesn't tell us whether the science will deliver, but it's a real change in the research landscape.

Aaron: The parent in me wants to say: great, but also, please don't oversell. Families have been burned by headlines before.

Jamie: That's fair. The article itself is careful to say these are announced investments and planned work. It doesn't report outcomes. And a huge investment can be genuinely important while still taking years to produce clinically useful answers.

Aaron: Staying with research, there's a genetics story that connects to that "we have something to chase" idea. Holly Barker wrote about three preprints in The Transmitter on 8 October 2026. The headline number is 253 high-confidence autism-linked genes, up from 72 in the same team's 2022 study.

Jamie: Right. The new gene-list analysis looked at exome sequences from 62,429 autistic people in the Autism Sequencing Consortium and three other major cohorts. Two of those cohorts, the Simons Simplex Collection and SPARK, are funded by the Simons Foundation, which also supports The Transmitter. The work identified 253 high-confidence genes and grouped them into six clusters based on overlap with schizophrenia, bipolar disorder, epilepsy, and other neurodevelopmental conditions.

Aaron: What do those clusters actually mean?

Jamie: They're a way of organizing genes by what else they're connected to. Genes associated with autism alone, or autism and schizophrenia, were less likely to harbor de novo variants than genes also implicated in neurodevelopmental conditions more generally. When the researchers grouped the six clusters into two broader categories, synapse assembly was more common among autism-specific genes, while transcriptional regulation was enriched among genes linked to a wider range of conditions.

Aaron: And the outcome piece?

Jamie: Children carrying a rare variant in a gene connected to many conditions were more likely to show developmental delays and less likely to reach developmental milestones than children carrying a variant in an autism-specific gene. That's a group-level finding. It does not tell you what will happen to one child. Mark Daly, one of the investigators, is quoted saying, "We are not yet at a point where individual genetic results can accurately predict patient trajectories." He also cautions that the six clusters are probabilistic but not predictive.

Aaron: That's the sentence I'd want every parent to hear. Genetic risk is not destiny.

Jamie: Yes, and the numbers help show why. In the third preprint, de novo variants accounted for 3.4 percent of the variation in people's genetic susceptibility to autism. Among people carrying spontaneous variants, half of that variance—about 1.7 percent—could be explained by just 15 genes, most associated with severe neurodevelopmental conditions. About 7 percent of autistic people carry a spontaneous variant predicted to increase the likelihood of having the condition. The 20 percent most constrained genes accounted for about 90 percent of the variation in genetic likelihood attributable to de novo variants.

Aaron: So a small number of genes with large effects, and many common variants with tiny effects.

Jamie: That's the picture. The forecasting analysis also predicted that many autism-linked genes remain undiscovered, including roughly 25 percent of genes strongly linked to the condition. And Maria Chahrour, who wasn't involved, notes that most autistic people still lack a rare-variant explanation and that cohorts need more ancestral diversity. That's an important limitation. The science is real, but it's incomplete.

Aaron: Now, a story that's a counterweight to all the "breakthrough" language. A highly cited 2017 Nature paper linking maternal gut bacteria to autism-like traits in mice got an expression of concern. That's not a retraction, right?

Jamie: Correct, an expression of concern. The Transmitter reported on 16 October 2026 that Nature issued the notice because of apparent data duplications. The paper has been cited more than 680 times. The notice cites recurring identical values for two sociability measures across multiple datasets in 10 different figures. The authors could not locate all the original raw data files after lab relocations.

Aaron: What happened in the review?

Jamie: The expression of concern notes a correction for a duplicated image that Sholto David flagged on PubPeer in September 2025. While reviewing that image issue, investigator Jun Huh went through the data and found what Dan Littman describes as a whole bunch of duplicate numbers. Huh couldn't verify the source and notified Nature. Nature's editor, Francesca Cesari, said the journal investigated carefully and, because the authors couldn't locate all the original raw data files, determined an expression of concern was the most appropriate course. All authors agreed except first author Sangdoo Kim and Soyoung Ha, who didn't respond to Nature's communications or couldn't be reached.

Aaron: Some of the authors say the conclusions still hold.

Jamie: Yes. Huh says the study's conclusions remain unchanged and have since been corroborated by subsequent studies. John Lukens says the core concepts have been reproduced and the data duplications shouldn't take away from what was reported. But critics are less sanguine. Mu Yang says the duplicated data are critical for the conclusions, and that the extent to which the duplications change the findings can only be evaluated by comparing incorrect data with correct raw data. Kevin Mitchell says research linking the gut microbiome to autism is plagued by conceptual and methodological flaws, and that the literature is all over the place.

Aaron: How should a general listener hold that?

Jamie: I'd say: don't treat one mouse study as a settled explanation for autism, and don't treat an expression of concern as proof that every related finding is wrong. It's a signal about data integrity and uncertainty. It also shows why replication and raw-data access matter. That's not exciting, but it's how the science earns trust.

Aaron: There's also a brief research roundup item about acetaminophen, or Tylenol. This one might relieve some parents who saw scary headlines.

Jamie: The roundup by Jill Adams, published 13 October 2026, summarizes a study exposing lab-grown brain tissue to acetaminophen at a stage modeling late first-trimester development. The tissue showed no changes in size, structure, cell survival, the connections between neurons, or the mix of developing brain cells. Some changes in gene activity appeared at the highest dose, but gene activity looked normal later. The roundup says the findings are consistent with large-scale studies showing that acetaminophen use during pregnancy does not increase the likelihood of having a child with autism.

Aaron: So the organoid study itself doesn't prove that. It's consistent with the larger studies.

Jamie: Exactly. The conclusion about likelihood comes from the large-scale studies cited as consistent with the organoid findings, not from the organoid experiment itself. The organoid work explores possible direct biological mechanisms. It doesn't report clinical outcomes. And the roundup doesn't give sample sizes, doses, effect estimates, or methods, so it's a brief summary rather than something to base personal medical decisions on. Anyone with questions about medication during pregnancy should talk with their clinician.

Aaron: Let's shift to everyday life. Three ADDitude advice pieces caught my eye: one by Ari Tuckman about ADHD-related social slip-ups, one by Sharon Saline about conversations and the APPLE mnemonic, and one by Caroline Maguire about oversharing. These are advice pieces, not research studies.

Jamie: Right. No sample sizes, no outcome data. They're practical guidance. The Tuckman piece uses three adults: Steph, who interrupts when she's excited or nervous; Roberto, who was told he looked lost in thought and bored; and James, who overcommitted and canceled plans at the last minute. The advice includes identifying two or three recurring patterns, using a discreet partner signal, repairing a misstep with a sincere explanation, making eye contact when you catch yourself drifting, asking for repetition, and checking your calendar before agreeing to something new.

Aaron: The Steph story is very human. She meets her boyfriend's parents, cuts them off to make her own points, and later sends a thank-you card explaining that her excitement got the best of her. That's not a cure for interrupting. It's repair.

Jamie: And repair matters. The article says people with ADHD often know what they should do but have trouble doing it in the moment. That's a practical distinction, not a moral failing. The Saline piece makes a similar point about unspoken social rules. It says assumptions that everyone knows these rules don't account for neurodiversity—some people with ADHD, learning differences, and autistic people may not understand them or may never have learned them, and anxiety can affect social skills too.

Aaron: The APPLE mnemonic is a lot. Can you unpack it without sounding like a corporate training slide?

Jamie: Sure. Ask to join a conversation and assess what's happening before jumping in. Pay attention to physical proximity and volume—where you're standing, how loud you are, whether you're matching the room. Participate with reflective statements like "So what you're saying is..." or "Oh, wow, you just got that new job. Fantastic." Lay off self-criticism; don't let the internal negative voice run the show. And enjoy connecting—share what's interesting about you and learn what's interesting about others. The Saline article also suggests a buddy signal for volume or overenthusiasm, and if you've spaced out, it suggests discreetly asking a nearby friend what's being discussed.

Aaron: The oversharing piece adds another layer. It talks about impulsivity, wanting to connect, and that feeling of clicking with someone after five minutes. The advice is to notice triggers, do some "social spying" to see what others share, gamify asking questions before talking about yourself, check trust and familiarity, assess your emotional state, and practice tighter stories. It also says practice, not perfection.

Jamie: Yes. The article frames oversharing as driven by impulsivity, a desire for connection, and social-skills challenges. It doesn't give prevalence estimates, and it makes some broad claims about neurodivergent minds that aren't backed by cited research in the piece. So I'd treat the strategies as optional tools, not a diagnosis or a rulebook. The article itself says it's not all or nothing—if a detail is edging into oversharing territory, you can steer toward a more neutral talking point instead of discarding it completely.

Aaron: As a parent, I worry these tips can become "act normal" homework. Especially for kids who are already being told their natural way of communicating is wrong.

Jamie: That's a real tension. The Saline piece does acknowledge that unspoken rules can be especially hard for neurodivergent people. I'd frame these as optional strategies a person can choose if they want a particular social outcome—not requirements for being acceptable. There's a difference between choosing to use a buddy signal because it helps you in a meeting and being told you must suppress who you are. Also, some of the body-language advice relies on general social norms and doesn't account for cultural or individual variation. So take what helps, leave the rest, and respect boundaries.

Aaron: For me, the through-line today is: big investments and gene lists are exciting, but they're not promises about one person's future. Research integrity matters. And everyday social advice is most useful when it's optional and respectful.

Jamie: That's a good summary. The ARIA story is about planned infrastructure; the genetics work is group-level and not yet predictive for individuals; the expression of concern is a caution about data integrity, not a verdict on every gut-brain study; the acetaminophen organoid item is consistent with larger studies but isn't clinical advice; and the social pieces are practical guidance without research evidence behind every claim.

Aaron: Thanks for listening to Living on the Spectrum. Article summaries and links to the original reporting are on the episode page. Take care, and we'll see you next time.

Jamie: See you next time.

References

• Private initiative makes ‘historic’ investment in autism research
• Highly cited autism paper earns expression of concern over data duplications
• Quote: Mark Daly on genetic results and patient trajectories
• Research roundup
• Is Your ADHD Causing Social Slip-Ups?
• The ADHD Guide to Naturally Flowing, 'Normal' Conversations
• How to Break Your Habit of Oversharing